drugset
Drugs / Everolimus
last change yesterday re-read 8 days ago

Everolimus

also known as RAD001 · Afinitor · Certican · EVR · EVE · Zortress · RAD001-Everolimus · EVL · +10 more

Small molecule targets HIF1A, MTOR via inhibition

Developed for
breast cancer · renal cell carcinoma · cancer · non-small cell lung carcinoma · disease related to solid organ transplantation · head and neck cancer · neuroendocrine neoplasm · tuberous sclerosis
+304 more · clear cell renal carcinoma · estrogen-receptor positive breast cancer · prostate cancer · colorectal cancer · hormone receptor-positive breast cancer · kidney cancer · pancreatic neuroendocrine tumor · cancer of unknown primary site · female breast carcinoma · gastric cancer · metastatic malignant neoplasm · triple-negative breast carcinoma · endometrial cancer · hepatocellular carcinoma · Her2-receptor negative breast cancer · carcinoid tumor · cytomegalovirus infection · diffuse large B-cell lymphoma · metastatic neoplasm · neuroendocrine carcinoma · plasma cell myeloma · transplant rejection · breast neoplasm · glioblastoma · lymphoma · mantle cell lymphoma · HER2 positive breast carcinoma · Hodgkins lymphoma · lung cancer · ovarian cancer · refractory malignant neoplasm · acute myeloid leukemia · B-cell chronic lymphocytic leukemia · central nervous system neoplasm · chronic renal failure syndrome · digestive system neuroendocrine neoplasm · leukemia · acute lymphoblastic leukemia · brain neoplasm · cholangiocarcinoma · diffuse intrinsic pontine glioma · digestive system cancer · epilepsy · gallbladder cancer · gastrin-producing neuroendocrine tumor · glucagonoma · kidney failure · malignant pancreatic neoplasm · neoplasm · NF2-related schwannomatosis · pancreatic endocrine carcinoma · pancreatic insulinoma · PPoma · soft tissue sarcoma · somatostatinoma · thyroid cancer · urinary bladder cancer · Waldenstrom macroglobulinemia · adenoid cystic carcinoma · anaplastic astrocytoma · angioimmunoblastic T-cell lymphoma · autosomal dominant polycystic kidney disease · chronic lymphocytic leukemia/small lymphocytic lymphoma · chronic transplant rejection · cutaneous melanoma · esophageal cancer · graft versus host disease · impaired renal function disease · liver cancer · lung neuroendocrine neoplasm · lymphangioleiomyomatosis · medullary thyroid gland carcinoma · meningioma · metastatic melanoma · myelodysplastic syndrome · pancreatic adenocarcinoma · post-transplant lymphoproliferative disease · primary peritoneal carcinoma · sarcoma · small cell lung carcinoma · subependymal giant cell astrocytoma · adult T-cell leukemia/lymphoma · anaplastic large cell lymphoma · autism · Burkitt lymphoma · carcinoma · castration-resistant prostate carcinoma · central nervous system cancer · childhood ependymoma · chronic graft versus host disease · classic Hodgkin lymphoma · colorectal adenocarcinoma · colorectal carcinoma · cutaneous neuroendocrine carcinoma · endometrial carcinoma · endometrial endometrioid adenocarcinoma · extranodal nasal NK/T cell lymphoma · fallopian tube cancer · fallopian tube carcinoma · gastroesophageal cancer · gastrointestinal stromal tumor · head and neck squamous cell carcinoma · hepatitis C virus infection · hepatosplenic T-cell lymphoma · hypopharynx squamous cell carcinoma · immunodeficiency disease · invasive breast carcinoma · kidney angiomyolipoma · kidney disorder · larynx verrucous carcinoma · liver disorder · MALT lymphoma · medulloblastoma · melanoma · mycosis fungoides and variants · nasal cavity and paranasal sinus squamous cell carcinoma · neurofibromatosis type 1 · nodal marginal zone B-cell lymphoma · non-Hodgkin lymphoma · oropharynx squamous cell carcinoma · osteoporosis · paraganglioma · peripheral T-cell lymphoma, not otherwise specified · Peutz-Jeghers syndrome · pheochromocytoma · plasma cell neoplasm · plexiform neurofibroma · primary cutaneous T-cell lymphoma · progesterone-receptor positive breast cancer · splenic marginal zone lymphoma · tongue cancer · transitional cell carcinoma · urothelial carcinoma · vascular malformation · verrucous carcinoma of oral cavity · acoustic neuroma · acute graft versus host disease · acute hepatitis C virus infection · acute leukemia of ambiguous lineage · adult glioblastoma · adult hepatocellular carcinoma · adult oligodendroglioma · age-related macular degeneration · ALK-negative anaplastic large cell lymphoma · anaplastic oligodendroglioma · angiolipoma · angiomyolipoma · anti-HLA hyperimmunization · arteriovenous hemangioma/malformation · astrocytoma (excluding glioblastoma) · atypical endometrial hyperplasia · atypical teratoid rhabdoid tumor · B-cell adult acute lymphocytic leukemia · B-cell lymphoma, unclassifiable, with features intermediate between diffuse large b-cell lymphoma and classical Hodgkin lymphoma · Birt-Hogg-Dube syndrome · BK-virus nephropathy · bone cancer · bone sarcoma · brain cancer · brain glioma · brain oligodendroglioma · breast carcinoma · carcinoid syndrome · carcinoma of lip · cervical cancer · cervical squamous cell carcinoma · childhood acute myeloid leukemia · childhood low-grade glioma · childhood malignant neoplasm · chondrosarcoma · choroidal neovascularization · chronic kidney disease · chronic myeloid leukemia · cirrhosis of liver · combined thymoma · coronary restenosis · differentiated thyroid carcinoma · diffuse astrocytoma · diffuse gastric adenocarcinoma · diffuse midline glioma, H3 K27M-mutant · disease related to hematopoietic stem cell transplant · end stage renal failure · Epstein-Barr virus-related tumor · esophageal adenocarcinoma · esthesioneuroblastoma · extrahepatic bile duct carcinoma · fibrolamellar hepatocellular carcinoma · follicular lymphoma · gastric intestinal type adenocarcinoma · gastric neoplasm · gastroesophageal junction adenocarcinoma · germ cell tumor · glioma · gliosarcoma · grade II glioma · grade III glioma · hemangioendothelioma · high grade astrocytic tumor · high grade malignant neoplasm · HIV infectious disease · hormone-resistant prostate carcinoma · Hutchinson-Gilford progeria syndrome · idiopathic subglottic stenosis · immunodeficiency-related disorder · intracranial meningioma · inverted papilloma · isolated focal cortical dysplasia · isolated focal cortical dysplasia type II · Kaposi's sarcoma · kidney neoplasm · large cell carcinoma · liver and intrahepatic bile duct neoplasm · liver failure · low grade glioma · low-grade astrocytoma · lung carcinoid tumor · lymphangioma · lymphoblastic lymphoma · lymphoepithelial-like carcinoma · lymphoproliferative syndrome · male breast carcinoma · malignant epithelial tumor of ovary · malignant germ cell tumor · malignant glioma · malignant mesothelioma · malignant peripheral nerve sheath tumor · malignant pleural mesothelioma · marginal zone lymphoma · metastatic malignant neoplasm in the brain · metastatic malignant neoplasm in the colon · metastatic prostate carcinoma · metastatic squamous cell carcinoma · myelofibrosis · myeloid leukemia · myocardial infarction · nasal cavity and paranasal sinus lethal midline granuloma · nasopharyngeal squamous cell carcinoma · non-functioning endocrine neoplasm · non-neoplastic nevus · oligoastrocytoma · oligodendroglioma · oral cavity mucoepidermoid carcinoma · osteosarcoma · ovarian carcinoma · ovarian endometrioid adenocarcinoma · ovarian germ cell tumor · ovarian seromucinous carcinoma · ovarian serous cystadenocarcinoma · ovarian serous surface papillary adenocarcinoma · overgrowth syndrome · pancreatic acinar cell carcinoma · pancreatic ductal adenocarcinoma · pancreatic gastrinoma · pancreatic neuroendocrine neoplasm · pancreatic neuroendocrine tumor G1 · papillary renal cell carcinoma · peripheral arterial disease · peritoneum cancer · poisoning · polyomavirus infectious disease · premature aging syndrome · primary aldosteronism · primary central nervous system lymphoma · primary cutaneous T-cell non-Hodgkin lymphoma · PTEN hamartoma tumor syndrome · renal carcinoma · renal cell adenocarcinoma · renal fibrosis · renal pelvis carcinoma · respiratory tract infectious disorder · rhabdomyosarcoma · Richter transformation · salivary gland cancer · salivary gland disorder · salivary gland squamous cell carcinoma · secondary malignant neoplasm · skin cancer · Sturge-Weber syndrome · synovial sarcoma · systemic mastocytosis · T-cell adult acute lymphocytic leukemia · T-lymphoblastic lymphoma · testicular cancer · thyroid gland carcinoma · thyroid Hurthle cell carcinoma · tuberculosis · undifferentiated carcinoma of nasopharynx · undifferentiated ovarian carcinoma · ureter cancer · uterine cancer · uterine corpus cancer · uterine corpus sarcoma · uveal melanoma · uveitis · vascular neoplasm · venous hemangioma · vestibulocochlear nerve neoplasm · VIPoma · viral infectious disease · acute coronary syndrome · digestive system neuroendocrine tumor, grade 1/2 · disease related to transplantation · thymus neoplasm · urinary bladder carcinoma
Investigated by
Novartis Pharmaceuticals · Novartis · National Cancer Institute (NCI) · M.D. Anderson Cancer Center · Dana-Farber Cancer Institute · Memorial Sloan Kettering Cancer Center
+471 more · Genentech, Inc. · Beth Israel Deaconess Medical Center · Emory University · Fudan University · Massachusetts General Hospital · Mayo Clinic · Brigham and Women's Hospital · SCRI Development Innovations, LLC · Alliance for Clinical Trials in Oncology · University of California, San Francisco · Yonsei University · Asan Medical Center · Children's Hospital Medical Center, Cincinnati · Bayer · Boston Children's Hospital · Eisai Inc. · Fox Chase Cancer Center · GlaxoSmithKline · Hospices Civils de Lyon · NYU Langone Health · SWOG Cancer Research Network · Samsung Medical Center · University of Chicago · Vanderbilt-Ingram Cancer Center · Academic Medical Center - University of Amsterdam · Amgen · Amsterdam UMC, location VUmc · City of Hope Medical Center · Erasmus Medical Center · Gustave Roussy, Cancer Campus, Grand Paris · Odense University Hospital · Pfizer · Swiss Cancer Institute · UNC Lineberger Comprehensive Cancer Center · University of Utah · Abramson Cancer Center at Penn Medicine · Assistance Publique - Hôpitaux de Paris · AstraZeneca · Chong Kun Dang Pharmaceutical · Daniel George, MD · Eli Lilly and Company · GBG Forschungs GmbH · Hannover Medical School · Herbert Hurwitz · Hospital do Rim e Hipertensão · Indiana University · Jonsson Comprehensive Cancer Center · Merck Sharp & Dohme LLC · Milton S. Hershey Medical Center · National Institute of Allergy and Infectious Diseases (NIAID) · National Institute on Aging (NIA) · OSI Pharmaceuticals · Peking University Cancer Hospital & Institute · Seoul National University Hospital · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Stemline Therapeutics, Inc. · Sun Yat-sen University · The Methodist Hospital Research Institute · The University of Texas Health Science Center at San Antonio · UMC Utrecht · University of California, Davis · University of Cologne · University of Michigan Rogel Cancer Center · University of Texas Southwestern Medical Center · Washington University School of Medicine · Yale University · iOMEDICO AG · AIO-Studien-gGmbH · ARCAGY/ GINECO GROUP · Aarhus University Hospital · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Centre Leon Berard · Charite University, Berlin, Germany · Chulalongkorn University · all 477 on the full record

Regulatory milestones approvals, filings & regulatory actions · 16 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Label expansions (12) US (FDA) AFINITOR — 2010-10-29 – 2021-12-30 fda.gov ↗
Label expansions (2) US (FDA) ZORTRESS — 2013-02-15 – 2016-10-12 fda.gov ↗
Approved EU (EMA) Afinitor — 2009-08-02 europa.eu ↗
Approved US (FDA) AFINITOR — 2009-03-30 fda.gov ↗

Trials 708 · started per year

today
US approved 2009
EU approved 2009
1
2
1
2
14
26
29
33
55
77
79
55
60
42
44
27
26
22
9
13
13
12
8
12
15
9
17
20002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 09 trials
Phase 0 NCT07095933 Jul → Dec 2026 expected epilepsy Xuanwu Hospital, Beijing Recruiting No outcome recorded
Phase 0 NCT06658093 Mar 2026 → Jul 2028 expected — The University of Texas Health Science Center at San Antonio Recruiting No outcome recorded
Phase 0 NCT05432518 Jun 2023 → Jul 2027 expected adult glioblastoma AHS Cancer Control Alberta Recruiting No outcome recorded
Phase 0 NCT05188118 Feb 2023 → Feb 2025 renal cell carcinoma Icahn School of Medicine at Mount Sinai Completed No outcome recorded
Phase 0 NCT05153668 Sep 2022 → Oct 2025 idiopathic subglottic stenosis Johns Hopkins University Completed No outcome recorded
Phase 0 NCT04135807 Mar 2020 → Jan 2028 expected anaplastic astrocytoma, anaplastic oligodendroglioma, brain oligodendroglioma, glioblastoma Oliver Jonas Recruiting No outcome recorded
Phase 0 NCT03834740 Jan 2019 → Feb 2022 brain glioma, glioblastoma St. Joseph's Hospital and Medical Center, Phoenix Completed No outcome recorded
Phase 0 NCT03578432 May 2018 → Nov 2019 head and neck cancer, salivary gland disorder University of Arizona Terminated No outcome recorded
Phase 0 NCT01880749 Jun 2013 → Dec 2019 NF2-related schwannomatosis, meningioma, vestibulocochlear nerve neoplasm NYU Langone Health Completed No outcome recorded
Phase 1143 trials
Phase 1 NCT07865130 Sep 2026 → Jun 2033 expected medulloblastoma Bożenna Dembowska Bagińska Not yet recruiting No outcome recorded
Phase 1 NCT07318324 May 2026 → Aug 2028 expected endometrial cancer M.D. Anderson Cancer Center Recruiting No outcome recorded
Phase 1 NCT06832189 Jan 2026 → Jun 2030 expected — National Institute of Allergy and Infectious Diseases (NIAID) Recruiting No outcome recorded
Phase 1 NCT06994572 May 2025 → Apr 2029 expected hepatocellular carcinoma Captor Therapeutics S.A. Not yet recruiting No outcome recorded
Phase 1 NCT05949658 May 2024 → Mar 2027 expected — University of Wisconsin, Madison Recruiting No outcome recorded
Phase 1 NCT05508906 Aug 2022 → Dec 2027 expected Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer Olema Pharmaceuticals, Inc. Active not recruiting No outcome recorded
Phase 1 NCT05293964 May 2022 → Dec 2024 overdue breast cancer Jiangsu Simcere Pharmaceutical Co., Ltd. Active not recruiting No outcome recorded
Phase 1 NCT04895748 Nov 2021 → Feb 2026 clear cell renal carcinoma Novartis Pharmaceuticals Terminated No outcome recorded Stop: Business
Phase 1 NCT04818632 Nov 2021 → Sep 2023 estrogen-receptor positive breast cancer AstraZeneca Completed No outcome recorded
Phase 1 NCT05490095 Jul 2021 → Jan 2022 — Sovargen Completed No outcome recorded
Show all 143 trials opens the full record — a long page
Phase 1/283 trials · 2 met primary · 4 missed
Phase 1/2 NCT07435584 Mar → Dec 2026 expected colorectal cancer Second Affiliated Hospital, School of Medicine, Zhejiang University Not yet recruiting No outcome recorded
Phase 1/2 NCT07002177 Jun 2025 → May 2028 expected estrogen-receptor positive breast cancer Forward Pharmaceuticals Co., Ltd. Recruiting No outcome recorded
Phase 1/2 NCT06682611 Nov 2024 → Nov 2026 expected — Shanghai Runshi Pharmaceutical Technology Co., Ltd Not yet recruiting No outcome recorded
Phase 1/2 NCT05563220 Jan 2023 → Dec 2026 expected breast cancer Stemline Therapeutics, Inc. Active not recruiting No outcome recorded
Phase 1/2 NCT04802759 Jun 2021 → May 2029 expected estrogen-receptor positive breast cancer Hoffmann-La Roche Recruiting No outcome recorded
Phase 1/2 NCT03697408 Feb 2019 → May 2024 overdue classic Hodgkin lymphoma University of Pennsylvania Active not recruiting No outcome recorded
Phase 1/2 NCT03805399 Oct 2018 → Dec 2022 triple-negative breast carcinoma Fudan University Unknown No outcome recorded
Phase 1/2 NCT03284957 Sep 2017 → Nov 2024 breast cancer Sanofi Terminated No outcome recorded Stop: Business
Phase 1/2 NCT02991807 Jun 2017 → Feb 2021 PTEN hamartoma tumor syndrome Boston Children's Hospital Completed Missed primary
Phase 1/2 NCT02985125 May 2017 → Jul 2019 pancreatic adenocarcinoma Georgetown University Completed No outcome recorded
Phase 2281 trials · 12 met primary · 32 missed
Phase 2 NCT07634601 Dec 2026 → Dec 2028 expected endometrial carcinoma Jonsson Comprehensive Cancer Center Not yet recruiting No outcome recorded
Phase 2 NCT07522801 Sep 2026 → Dec 2029 expected — Philippe ROUSSELOT Not yet recruiting No outcome recorded
Phase 2 NCT07619950 Jul 2026 → Nov 2028 expected bone cancer Yonsei University Not yet recruiting No outcome recorded
Phase 2 NCT07124078 May 2026 → Jan 2029 expected chronic graft versus host disease Incyte Corporation Recruiting No outcome recorded
Phase 2 NCT07477548 Apr 2026 → Oct 2030 expected arteriovenous hemangioma/malformation, hemangioendothelioma, lymphangioma, non-neoplastic nevus +2 Yonsei University Not yet recruiting No outcome recorded
Phase 2 NCT07340541 Feb 2026 → Jun 2031 expected estrogen-receptor positive breast cancer, triple-negative breast carcinoma UNC Lineberger Comprehensive Cancer Center Recruiting No outcome recorded
Phase 2 NCT07191353 Oct 2025 → Mar 2027 expected osteoporosis Odense University Hospital Recruiting No outcome recorded
Phase 2 NCT07037238 Jul 2025 → Jul 2026 overdue vascular malformation Xuanwu Hospital, Beijing Recruiting No outcome recorded
Phase 2 NCT06972758 Jul 2025 → Jul 2030 expected hepatocellular carcinoma Yonsei University Not yet recruiting No outcome recorded
Phase 2 NCT06730672 Dec 2024 → Dec 2027 expected renal carcinoma Sun Yat-sen University Recruiting No outcome recorded
Show all 281 trials opens the full record — a long page
Phase 2/310 trials · 1 missed
Phase 2/3 NCT07218575 Sep 2026 → Sep 2030 expected Bannayan-Riley-Ruvalcaba syndrome, Cowden disease, Lhermitte-Duclos disease, Martsolf syndrome +1 Boston Children's Hospital Not yet recruiting No outcome recorded
Phase 2/3 NCT03458221 Jan 2023 → Oct 2026 expected ovarian cancer Gynaecologisch Oncologisch Centrum Zuid Recruiting No outcome recorded
Phase 2/3 NCT05833815 Nov 2022 → Dec 2024 overdue gallbladder cancer Banaras Hindu University Recruiting No outcome recorded
Phase 2/3 NCT02860494 Dec 2020 → Dec 2023 vascular neoplasm Hospices Civils de Lyon Withdrawn No outcome recorded Stop: Business
Phase 2/3 NCT03285802 Sep 2017 → Feb 2019 uterine cancer Greater Baltimore Medical Center Completed No outcome recorded
Phase 2/3 NCT01878786 Jun 2013 → Nov 2017 — Matthew Cooper Terminated No outcome recorded
Phase 2/3 NCT01730209 Nov 2012 → Nov 2015 autism, tuberous sclerosis Erasmus Medical Center Unknown Missed primary
Phase 2/3 NCT01023542 Jun 2011 → Jul 2014 impaired renal function disease University of Regensburg Unknown No outcome recorded
Phase 2/3 NCT01009957 Jun 2008 → Jan 2014 autosomal dominant polycystic kidney disease A. Manzoni Hospital Terminated No outcome recorded
Phase 2/3 NCT00117702 Oct 2005 → May 2008 graft versus host disease Technical University Dresden Terminated No outcome recorded
Phase 381 trials · 13 met primary · 16 missed
Phase 3 NCT07739914 Aug 2026 → Jun 2029 expected liver disorder Hannover Medical School Recruiting No outcome recorded
Phase 3 NCT07407517 Feb 2026 → Feb 2033 expected female breast carcinoma, triple-negative breast carcinoma Fudan University Not yet recruiting No outcome recorded
Phase 3 NCT07239271 Nov 2025 → Dec 2027 expected HER2 positive breast carcinoma Cancer Institute and Hospital, Chinese Academy of Medical Sciences Not yet recruiting No outcome recorded
Phase 3 NCT07165418 Sep 2025 → Dec 2028 expected renal cell carcinoma Peking University Cancer Hospital & Institute Not yet recruiting No outcome recorded
Phase 3 NCT06382948 Dec 2024 → Sep 2027 expected Her2-receptor negative breast cancer, estrogen-receptor positive breast cancer MedSIR Recruiting No outcome recorded
Phase 3 NCT06680921 Nov 2024 → Aug 2028 expected breast cancer Jiangsu Simcere Pharmaceutical Co., Ltd. Recruiting No outcome recorded
Phase 3 NCT05954442 Sep 2023 → Aug 2025 overdue triple-negative breast carcinoma Fudan University Recruiting No outcome recorded
Phase 3 NCT05429684 Jan 2021 → Feb 2024 HER2 positive breast carcinoma First Affiliated Hospital Xi'an Jiaotong University Unknown No outcome recorded
Phase 3 NCT04258423 Dec 2019 → Jun 2020 kidney failure Indiana University Terminated No outcome recorded
Phase 3 NCT03839940 Jun 2019 → Jan 2021 cancer Alliance for Clinical Trials in Oncology Terminated Missed primary Stop: Enrollment
Phase 474 trials · 8 met primary · 8 missed
Phase 4 NCT07570433 Apr 2026 → Jan 2028 expected cytomegalovirus infection Oriol Manuel Not yet recruiting No outcome recorded
Phase 4 NCT06942156 Aug 2025 → Dec 2030 expected — Chong Kun Dang Pharmaceutical Not yet recruiting No outcome recorded
Phase 4 NCT05252585 May 2023 → Oct 2026 expected kidney angiomyolipoma Novartis Pharmaceuticals Active not recruiting No outcome recorded
Phase 4 NCT04849533 Apr 2021 → Jul 2023 transplant rejection University of Cincinnati Unknown No outcome recorded
Phase 4 NCT04867720 Mar 2021 → Oct 2022 — Chong Kun Dang Pharmaceutical Unknown No outcome recorded
Phase 4 NCT04471441 Jun 2020 → Jul 2024 — Chong Kun Dang Pharmaceutical Completed No outcome recorded
Phase 4 NCT04177095 Feb 2020 → Sep 2021 transplant rejection Massachusetts General Hospital Completed No outcome recorded
Phase 4 NCT03797196 Jul 2019 → Jun 2025 overdue disease related to solid organ transplantation University Medical Center Groningen Active not recruiting Missed primary
Phase 4 NCT03525834 Nov 2018 → Sep 2020 kidney angiomyolipoma Novartis Pharmaceuticals Completed No outcome recorded
Phase 4 NCT03216967 Jan 2018 → Aug 2024 BK-virus nephropathy University Hospital, Strasbourg, France Completed Missed primary
Phase not applicable22 trials · 1 missed
— NCT07144150 Apr 2026 → Sep 2028 expected peripheral arterial disease Cook Research Incorporated Recruiting No outcome recorded
— NCT04199026 Feb 2025 → Dec 2028 expected sarcoma M.D. Anderson Cancer Center Recruiting No outcome recorded
— NCT06317298 Feb 2024 → Aug 2025 clear cell renal carcinoma Peking University First Hospital Unknown No outcome recorded
— NCT03955172 Dec 2020 → Dec 2027 expected chronic transplant rejection Hospices Civils de Lyon Recruiting No outcome recorded
— NCT04906304 Jan → Jul 2020 cytomegalovirus infection Shahid Beheshti University of Medical Sciences Completed No outcome recorded
— NCT02736227 Mar 2016 → Mar 2021 — Northwestern University Completed No outcome recorded
— NCT02551718 Sep 2015 → Jun 2020 acute leukemia of ambiguous lineage, acute lymphoblastic leukemia University of Washington Completed No outcome recorded
— NCT02109913 Mar 2014 → Jan 2021 hormone receptor-positive breast cancer Amsterdam UMC, location VUmc Unknown No outcome recorded
— NCT01936519 Dec 2013 → Jul 2019 immunodeficiency disease, kidney failure Milton S. Hershey Medical Center Completed No outcome recorded
— NCT02013089 Dec 2013 → May 2017 digestive system cancer Sun Yat-sen University Unknown No outcome recorded
Phase not stated5 trials
— NCT00149981 — disease related to solid organ transplantation Novartis Pharmaceuticals No longer available No outcome recorded
— NCT00655252 — renal cell carcinoma Novartis Pharmaceuticals No longer available No outcome recorded
— NCT03493165 — uterine corpus sarcoma The University of Texas Health Science Center at San Antonio No longer available No outcome recorded
— NCT05108740 — hormone receptor-positive breast cancer Novartis Pharmaceuticals No longer available No outcome recorded
— NCT03493152 — gastrointestinal stromal tumor The University of Texas Health Science Center at San Antonio No longer available No outcome recorded
Comparator or background therapy116 trials
Phase 0 NCT02134288 Comparator Apr 2014 → Dec 2018 — Ohio State University Terminated No outcome recorded
Phase 1 NCT05501769 Background Sep 2022 → Jul 2024 breast cancer Arvinas Estrogen Receptor, Inc. Completed No outcome recorded
Phase 1 NCT05189717 Background Feb 2022 → Oct 2024 breast cancer Shandong Suncadia Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT02577458 Background Sep 2015 → Mar 2018 renal cell carcinoma AnewPharma Unknown No outcome recorded
Phase 1 NCT02454478 Background Jul 2015 → May 2017 renal cell carcinoma Eisai Inc. Completed No outcome recorded
Show all 116 trials opens the full record — a long page

Press releases naming this drug 46 releases

DateIssuerRelease
2025-12-03 Mateon Therapeutics Oncotelic and Sapu Nano Announces New PK Data Demonstrating IV Sapu003 Reduces GI Accumulation of Everolimus up to 67-Fold Compared With Oral Dosing oncotelic.com ↗
2025-10-31 NATCO Pharma Ltd. NATCO Announces Launch of its Everolimus Tablets, 1 mg, (generic of Zortress®) natcopharma.co.in ↗
2025-10-30 Mateon Therapeutics Sapu Nano to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus) oncotelic.com ↗
2025-10-23 Mateon Therapeutics Oncotelic to present at the 2025 San Antonio Breast Cancer Symposium (SABCS) Highlighting Sapu003 (Deciparticle™ Everolimus) oncotelic.com ↗
2025-01-30 NATCO Pharma Ltd. NATCO announces approval of its Abbreviated New Drug Application (ANDA) for Everolimus tablets for Oral Suspension (generic of AFINITOR DISPERZ®) natcopharma.co.in ↗
2025-01-23 Impax Laboratories, LLC Amneal Receives U.S. FDA Approval for Memantine/Donepezil Extended-Release Capsules and Everolimus Tablets for Oral Suspension, and Tentative U.S. FDA Approval for Rifaximin amneal.com ↗
2024-08-05 Upsher-Smith Laboratories Upsher-Smith Expands Rare Disease Portfolio with Launch of Torpenz™ (everolimus) Tablets upsher-smith.com ↗
2023-10-21 Merck Sharp & Dohme LLC Merck’s WELIREG® (belzutifan) Significantly Improved Progression-Free Survival and Objective Response Rates Versus Everolimus in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) merck.com ↗
2021-10-29 Pharmascience Inc. Pharmascience Canada est fière de lancer le médicament générique pms-EVEROLIMUS 2.5 mg, 5 mg et 10 mg pharmascience.com ↗
2021-10-01 NATCO Pharma Ltd. NATCO announces launch of its 10mg strength for Everolimus Tablets (generic for Afinitor®) in the US market natcopharma.co.in ↗
2021-05-22 NATCO Pharma Ltd. NATCO receives final approval for Everolimus tablets (generic for ZORTRESS9 ) in the US market natcopharma.co.in ↗
2021-02-15 Eisai Inc. LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma LENVIMA Plus KEYTRUDA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib LENVIMA Plus Everolimus Significantly Improved PFS and Objective Response Rate Versus Sunitinib First Results From Pivotal CLEAR Study (Study 307/KEYNOTE-581) Presented at 2021 Genitourinary Cancers Symposium (ASCO GU) and Published in the New England Journal of Medicine eisai.com ↗

Evidence & citations 23 cited values

Every value below carries the sentence it was read from. 854 sources stand behind the page.

FieldValueCited text
Known as Everolimus “The BAT in this study was identified by the investigator prior to patient randomization among the following treatments currently used in this setting: anti-thymocyte globulin...” NCT02913261 ↗
720

“The BAT in this study will freely be identified by the Investigator prior to patient randomization and may include treatments such as: anti-thymocyte globulin (ATG),...” NCT04118556 ↗

“The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin,...” NCT04135807 ↗

“A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation...” NCT02040584 ↗

“We have recently demonstrated that RAD001(everolimus),an mTOR inhibitor, although with only modest growth inhibitory effects as a single agent, has significant synergistic...” NCT00632268 ↗

“Participants will receive any one of the following systemic BATs based on the Investigator's decision: mycophenolate mofetil (MMF), extracorporeal photopheresis (ECP),...” NCT04629833 ↗

“In total, 136 patients will be randomized in a 2:1 ratio to [177Lu]Lu-DOTATATE (≤4 doses of 7.4 GBq given every 4 wk) or local standard of care (hydroxyurea, bevacizumab,...” PMID 40774695 ↗ Jan 2026

“Stepwise reduction in the dose, and ultimate discontinuation of, all non-belatacept immunosuppression (mycophenolate, sirolimus, everolimus, prednisone) guided by monitoring of...” NCT04177095 ↗

“Participants with PIK3CA gene mutations will receive a drug called Everolimus, which inhibits a protein called AKT that is thought to be a key factor in the development and...” NCT02208583 ↗

“We performed a multi-institutional, single-arm, phase II study of RAD001(everolimus), an oral inhibitor of mTOR, in patients who experienced treatment failure on first-line...” PMID 19047305 ↗ Dec 2008

“Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously...” NCT00935961 ↗

Show 710 more sources
Known as Afinitor “Everolimus (Afinitor) is a single agent which was evaluated and demonstrated efficacy in randomized phase III study (RECORD-1) in metastatic RCC patients after failure of...” NCT02056587 ↗
13

“An Open-label, Single-dose Study to Assess the Pharmacokinetics of Oral Everolimus (Afinitor®) in Subjects With Impaired Hepatic Function” NCT00968591 ↗

“Therefore, everolimus (Afinitor®) is being tested in specific diseases to stop cells from growing too fast (as in cancer).” NCT02188550 ↗

“test two of these drugs, Rapamycin (Sirolimus) and Everolimus (Afinitor), in healthy older adults” NCT06658093 ↗

“Everolimus (Afinitor) 10 mg tablet once daily.” NCT01865747 ↗

“Oral Everolimus (RAD001, Afinitor®)” NCT01379521 ↗

“Everolimus (Afinitor) tablets” NCT07865130 ↗

“Everolimus (Afinitor) tablets” NCT07435584 ↗

“Everolimus (Afinitor®)” NCT02113800 ↗

“Everolimus (Afinitor®)” NCT06789900 ↗

“Everolimus (Afinitor®)” NCT01801137 ↗

Show 3 more sources
Known as AfinitorTM “Everolimus (AfinitorTM) is approved by the FDA for the treatment of advanced renal cell carcinoma” NCT01061788 ↗
Known as Afintor “* Everolimus (Afintor™) is a pill that works by blocking the activity of a substance in the body known as mTOR (mammalian target of rapamycin).” NCT01055795 ↗
Known as BU-Everolimus “Drug: BU-Everolimus” NCT01023542 ↗
Known as Certican “Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation” NCT01706471 ↗
13

“everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml” NCT01028092 ↗

“Valganciclovir will be administered and Certican (everolimus) will be added as immunosuppression” NCT00828503 ↗

“Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg.” NCT01023815 ↗

“Commercially available everolimus (Certican®), oral route, was used.” NCT02864706 ↗

“Everolimus (Certican®) and reduced dose of Cyclosporine A (Neoral®)” NCT02328963 ↗

“Patients will received everolimus (CERTICAN), oral form” NCT03955172 ↗

“Everolimus (Certican)” NCT00098007 ↗

NCT01596062 ↗

NCT00443508 ↗

NCT00504543 ↗

Show 3 more sources
Known as Certirobell “This study aims to evaluate the efficacy and safety of everolimus (Certirobell®) as adjuvant therapy in high-risk HCC patients following curative resection.” NCT06972758 ↗
Known as ERL “different immunosuppressive regimens (cyclosporine A [CsA]/MMF, Tacr/MMF, Tacr/MMF with conversion to Tacr/Everolimus [ERL]) or by cytokine promoter gene polymorphisms may...” NCT00160966 ↗
Known as EVE “We subsequently tested the effects of transient versus chronic inhibition of autophagy with chloroquine or hydroxychloroquine (HCQ) and mTOR signaling with rapamycin (RAPA) or...” PMID 40897974 ↗ Sep 2025
4

“We report a single-center phase I/II trial exploring the combination of everolimus (EVE) and mycophenolate mofetil (MMF) as calcineurin inhibitor (CNI)-free GVHD prophylaxis” PMID 33755792 ↗ Mar 2021

“Everolimus (EVE) and sorafenib (SOR) combination was associated with synergistic activity in preclinical models.” PMID 36840749 ↗ Feb 2023

“Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients” NCT01927588 ↗

“patients receiving everolimus (EVE) and exemestane (EXE)” PMID 33413212 ↗ Jan 2021
Known as Everolimus: Certican “Everolimus: Certican®” NCT01509560 ↗
Known as EVL “Kidney transplant manteinance treatment with Tacrolimus (TAC) to achieve 4-6 ng/mL trough levels, Everolimus (EVL) to achieve 3-8 ng/mL trough levels and Corticosteroids (CS)...” NCT04936971 ↗
2

“followed by either steroid withdrawal (CsA/MPA) or replacement of cyclosporine with everolimus (EVL)” PMID 33277746 ↗ Dec 2020

“Drug: Everolimus(EVL)” NCT02137239 ↗
Known as EVR “Here, in this randomized, multicenter, controlled trial (BKEVER study), we sought to evaluate the impact of everolimus (EVR) in facilitating the clearance of BKPyV compared to...” PMID 39490986 ↗ Oct 2024
10

“Participants were randomised (1:1) to receive everolimus with reduced-exposure calcineurin inhibitor (EVR+rCNI) or mycophenolic acid with standard-exposure CNI (MPA+sCNI).” PMID 34620664 ↗ Oct 2021

“Everolimus (EVR) was associated with lower incidence of viral infections and also the lowest incidence of neoplasms.” NCT01653041 ↗

“were randomized to receive everolimus (EVR) + mycophenolic acid (MPA) or were maintained on tacrolimus (TAC) + MPA.” PMID 27648523 ↗ Oct 2016

“Notch signaling, possibly modulated by everolimus (EVR), is essential for processes involved in CAV.” PMID 30312541 ↗ Nov 2018

“and everolimus (EVR), have distinct pharmacokinetic/pharmacodynamics properties.” PMID 37525373 ↗ Aug 2023

“receive everolimus + reduced-exposure tacrolimus (EVR + rTAC; n = 52)” PMID 32406111 ↗ Jun 2020

“start everolimus+reduced tacrolimus (EVR+rTAC)” PMID 29237235 ↗ Jan 2018

“everolimus (EVR), low-dose tacrolimus (LTac)” PMID 28141897 ↗ Mar 2017

“everolimus (EVR) + reduced tacrolimus (TAC)” PMID 28817434 ↗ Dec 2017

“everolimus (EVR)” PMID 33988338 ↗ Feb 2022
Known as RAD “This is a treatment protocol designed only to provide access to everolimus (RAD) for maintenance immunosuppression.” NCT00149981 ↗
Known as RAD001 “This study will assess whether everolimus (RAD001) is effective in preventing cyst and kidney expansion as well as worsening of renal function in patients with ADPKD and...” NCT00414440 ↗
180

“We conducted a phase Ib trial combining RAD001 (everolimus), an allosteric inhibitor of mTORC1, and conventional chemotherapy, in AML patients under 65 years of age at first...” PMID 23321953 ↗ Jan 2013

“A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing...” PMID 22160854 ↗ Dec 2011

“North Central Cancer Treatment Group Phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in patients with newly diagnosed...” PMID 20864273 ↗ Sep 2010

“Everolimus (RAD-001) is an orally active rapamycin analogue shown in preclinical data to produce cytostatic cell inhibition, which may be potentially beneficial in treating melanoma.” PMID 29666297 ↗ Apr 2018

“A Phase II Study of Carboplatin (CBDCA), Paclitaxel (TAXOL), and Everolimus (RAD001) in Previously Untreated Patients With Measurable Disease With Cancer of Unknown Primary (CUP)” NCT00936702 ↗

“UPCC 36315 A Phase II Study Of Everolimus (RAD001) And Lenvatinib (E7080) In Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Lenvatinib alone” NCT03139747 ↗

“A Phase I Trial to Evaluate Acute and Late Toxicities of Concurrent Treatment With Everolimus (RAD001) and Radio-Hormonotherapy in High-risk Prostate Cancer.(RHOMUS)” NCT00943956 ↗

“RTOG 0913: a phase 1 study of daily everolimus (RAD001) in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.” PMID 23725999 ↗ May 2013

“RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone.” NCT00496600 ↗

“Phase II study of temozolomide (TMZ) and everolimus (RAD001) therapy for metastatic melanoma: a North Central Cancer Treatment Group study, N0675.” PMID 23357973 ↗ Aug 2014

Show 170 more sources
Known as RAD001-Everolimus “RAD001 (Everolimus)” NCT01226056 ↗
3

“RAD001 (everolimus)” NCT01042782 ↗

“RAD001 (Everolimus)” NCT01063478 ↗

“RAD001-Everolimus” NCT00613132 ↗
Known as RAD001C “experimental drug RAD001C (RAD001, Everolimus)” NCT00187174 ↗
Known as sirolimus “Everolimus (sirolimus) is an inhibitor of the mammalian target of rapamycin (mTOR).” NCT07095933 ↗
Known as Votubia “Verum and placebo were provided by Novartis (Basel, Switzerland), including funding to cover the manufacturing and provision of everolimus (Votubia) tablets and the...” PMID 36049557 ↗ Aug 2022
2

“PTEN-loss only Votubia® (everolimus): 2.5 mg tablets.” NCT02233049 ↗

“Votubia” NCT07634601 ↗
Known as Zortress “The purpose of this study is to test the safety and effectiveness of everolimus (Zortress®) in preventing antibody formation in patients with chronic failing kidney transplants.” NCT01636466 ↗
4

“Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation” NCT02736227 ↗

“Patients are supplied everolimus (Zortress) + prograf” NCT01911546 ↗

“Zortress® /Everolimus” NCT01612299 ↗

“Zortress” NCT07634601 ↗
Action Inhibit “designed to block proteins that are important in the development and growth of cancer” NCT00081874 ↗
Modality Small molecule “Everolimus is a semisynthetic macrocyclic lactone” NCT00117702 ↗
Route Oral “you will receive treatment with RAD001 by mouth every day” NCT00081874 ↗
Target MTOR “the mammalian target-of-rapamycin inhibitor everolimus” PMID 20871262 ↗ Oct 2010